Lycia Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LYCA | LYKALABS.NS | ALMS | 2126.HK | ABCL | LKFT | |
|---|---|---|---|---|---|---|
| Market cap | 1.51B | 2.79B | 822.69M | 1.11B | 3.98B | 2.25B |
| P/E (TTM) | — | — | — | — | — | 3.2 |
| Forward P/E | — | — | -2.2 | -3.0 | -16.1 | -28.6 |
| Price/book | -3.2 | 3.0 | 1.8 | 2.0 | 4.2 | 12.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −3.60% | −19.26% | +38.77% | −31.72% | +171.08% | +9.26% |
| Today | +4.78% | +2.00% | −2.96% | +7.91% | +0.82% | +6.03% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LYCA news ›Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening Seagate Simplifies…
Lycia Therapeutics Jumps 67% in Upsized IPO, Closes at $30
Briefs Finance helps everyday people get better with money and invest with confidence, from getting out of debt all the way to investing like an expert. It starts with Market Briefs, a free five-minute daily newsletter, and grows into…
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
Carroll County Mirror-Democrat SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (âLyciaâ) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development
More from 1 other outlet
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
The South San Francisco, California-based company is seeking to raise up to $264.6 million in the IPO by offering 14.7 million shares priced between $16 and $18 apiece. The healthcare sector has anchored the fall IPO window this year in an…
Lycia Therapeutics, Inc. (LYCA) Competitor Stock Analysis
Seeking Alpha Invest smarter in volatile marketsMake informed decisions with the data, context, and analysis behind today’s market moves, with unlimited access to breaking stock news and free investing newsletters.
Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline
Lycia Therapeutics' IPO, if fairly priced, is likely to attract strong interest, given early positive data and solid biopharma performance. Read more on LYCA. - Lycia Therapeutics is a clinical-stage biopharma targeting autoimmune and…
Lycia Therapeutics files for IPO with LYTAC platform and Phase I food allergy data
South San Francisco-based Lycia Therapeutics, which develops extracellular protein degraders for autoimmune and allergic diseases, has submitted an amended draft registration statement to the SEC for a proposed IPO. The document does not…
Lycia Therapeutics files for a $100 million IPO, targeting food allergies and autoimmune diseases
LYCA IPO News - Lycia Therapeutics files for a $100 million IPO, targeting food allergies and autoimmune diseases renaissancecapital.com Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves'…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- allsci.com1
- briefs.co1
- kfgo.com1
- mycarrollcountynews.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.